EIF4G1 and familial pancreatic carcinoma: Interestingly, 100% patients (n = 96) of QCMG dataset for Pancreatic cancer showed up-regulation in EIF4G1 (Fig. 4i), another dataset for Pancreatic cancer patients showed a range of 7 to 9% of amplification and or up-regulation in EIF4G1 (Fig. 4i).